NO20051714L - Langtidsvirkende erytropoietiner som opprettholder vevsbeskyttende aktivitet til endogent erytropoietin - Google Patents

Langtidsvirkende erytropoietiner som opprettholder vevsbeskyttende aktivitet til endogent erytropoietin

Info

Publication number
NO20051714L
NO20051714L NO20051714A NO20051714A NO20051714L NO 20051714 L NO20051714 L NO 20051714L NO 20051714 A NO20051714 A NO 20051714A NO 20051714 A NO20051714 A NO 20051714A NO 20051714 L NO20051714 L NO 20051714L
Authority
NO
Norway
Prior art keywords
long
acting
erythropoietins
tissue protective
protective activity
Prior art date
Application number
NO20051714A
Other languages
English (en)
Inventor
Michael Brines
Carla Cerami
Anthony Cerami
John Smart
Original Assignee
Warren Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warren Pharmaceuticals Inc filed Critical Warren Pharmaceuticals Inc
Publication of NO20051714L publication Critical patent/NO20051714L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/10—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using coupling agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • AIDS & HIV (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)

Abstract

2005- -06- 0 6 Sammendrag O. nr. E39946 Fremgangsmåter for å øke hematokritt hos et individ mens de opprettholder de vevsbeskyttende endogene aktivitetene gjennom administrasjon av en farmasøytisk forbindelse som inneholder kjemisk modifisert langtidsvirkende erytropoietin. Også angitt er de nye kjemisk modifiserte langtidsvirkende erytropoietinene, fremgangsmåter for produksjon av de kjemisk modifiserte, langtidsvirkende erytropoietiner, og sammensetninger som omfatter de kjemisk modifiserte langtidsvirkende erytropoietinene.
NO20051714A 2002-09-09 2005-04-06 Langtidsvirkende erytropoietiner som opprettholder vevsbeskyttende aktivitet til endogent erytropoietin NO20051714L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40902002P 2002-09-09 2002-09-09
PCT/US2003/028073 WO2004022577A2 (en) 2002-09-09 2003-09-09 Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin

Publications (1)

Publication Number Publication Date
NO20051714L true NO20051714L (no) 2005-06-06

Family

ID=31978712

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20051714A NO20051714L (no) 2002-09-09 2005-04-06 Langtidsvirkende erytropoietiner som opprettholder vevsbeskyttende aktivitet til endogent erytropoietin

Country Status (15)

Country Link
EP (1) EP1545586A4 (no)
JP (1) JP2006511468A (no)
KR (1) KR20050083682A (no)
CN (2) CN101371920A (no)
AU (1) AU2003273297A1 (no)
BR (1) BR0314152A (no)
CA (1) CA2497960A1 (no)
EA (1) EA007812B1 (no)
IL (1) IL174178A0 (no)
IS (1) IS7731A (no)
MX (1) MXPA05002617A (no)
NO (1) NO20051714L (no)
PL (1) PL375741A1 (no)
WO (1) WO2004022577A2 (no)
ZA (1) ZA200505423B (no)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7718363B2 (en) 2003-04-25 2010-05-18 The Kenneth S. Warren Institute, Inc. Tissue protective cytokine receptor complex and assays for identifying tissue protective compounds
WO2006061853A2 (en) * 2004-12-10 2006-06-15 Serum Institute Of India Limited Novel erythropoietic compounds and a process for producing erythropoietic compounds
TWI376234B (en) 2005-02-01 2012-11-11 Msd Oss Bv Conjugates of a polypeptide and an oligosaccharide
HUE035655T2 (en) 2005-08-05 2018-05-28 Araim Pharmaceuticals Inc Tissue protective peptides and their use
NZ621196A (en) 2008-01-22 2015-08-28 Araim Pharmaceuticals Inc Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
CN101671388B (zh) * 2008-09-09 2013-01-02 曹国栋 血脑屏障穿透性促红细胞生成素及其应用
RU2475273C1 (ru) * 2012-04-02 2013-02-20 Юлия Николаевна Козлова Способ получения полимерного цемента медицинского назначения
CN102746405B (zh) * 2012-07-24 2013-08-21 深圳赛保尔生物药业有限公司 重组人促红素的连续聚乙二醇化反应方法
RU2664588C2 (ru) * 2015-11-05 2018-08-21 Закрытое Акционерное Общество "Биокад" Пролонгированный фактор эритропоэза человека и лекарственное средство на его основе
US10864253B2 (en) 2016-04-29 2020-12-15 Araim Pharmaceuticals, Inc. Tissue protective peptides for preventing and treating diseases and disorders associated with tissue damage
CN112741895A (zh) * 2021-01-19 2021-05-04 中国人民解放军陆军军医大学 Epo类似物在制备治疗脓毒症药物中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2291B1 (en) * 1999-07-02 2005-09-12 اف . هوفمان لاروش ايه جي Erythropoietin derivatives
WO2001081405A2 (en) * 2000-04-21 2001-11-01 Amgen Inc. Methods and compositions for the prevention and treatment of anemia
JP3967594B2 (ja) * 2000-05-15 2007-08-29 エフ．ホフマン−ラ ロシュ アーゲー 新しい薬剤組成物

Also Published As

Publication number Publication date
CN1729015A (zh) 2006-02-01
WO2004022577A2 (en) 2004-03-18
ZA200505423B (en) 2008-08-27
EP1545586A2 (en) 2005-06-29
MXPA05002617A (es) 2005-09-08
EA200500473A1 (ru) 2005-10-27
WO2004022577A3 (en) 2004-09-16
EA007812B1 (ru) 2007-02-27
BR0314152A (pt) 2005-07-12
CN101371920A (zh) 2009-02-25
IS7731A (is) 2005-03-08
PL375741A1 (pl) 2005-12-12
JP2006511468A (ja) 2006-04-06
EP1545586A4 (en) 2007-09-26
KR20050083682A (ko) 2005-08-26
CA2497960A1 (en) 2004-03-18
IL174178A0 (en) 2006-08-01
AU2003273297A8 (en) 2004-03-29
AU2003273297A1 (en) 2004-03-29

Similar Documents

Publication Publication Date Title
DE50009736D1 (de) Biphenylderivate, ihre herstellung und ihre verwendung als mtp-inhibitor
SE0001899D0 (sv) New compounds
NO20011721D0 (no) N-aralkylaminotetraliner som ligander for neuropeptid Y Y5 reseptor
BR0214343A (pt) Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1
CL2010000606A1 (es) Uso de derivados de eritropoyetina en la preparacion de un medicamento util para proteger, mantener, mejorar o recuperar la viabilidad de celulas que responden a eritropoyetina en condiciones anomalas que afectan las celulas, tejidos u organos asociados; derivados de eritropoyetinas y composicion que las comprende (divisional de la solicitud 3188-2001).
MY119231A (en) Novel lipoic acid derivatives, their preparation, and pharmaceutical compositions containing them
SE9504661D0 (sv) New compounds
NO20014485D0 (no) Nye forbindelser og sammensetninger som proteaseinhibitorer
HUP0104718A2 (hu) Mikronizált eplerenon kompozíciók és eljárás az előállításukra
MXPA03006841A (es) 4-fluoro-n-indan-2-il-benzamida y su uso como producto farmaceutico.
DK1047397T3 (da) Topiske præparater til forögelse af glutathionproduktion
IT1312377B1 (it) Composizioni a base di acido tiottico, cisteina e/o n-acetil cisteinada utilizzarsi in preparazioni farmaceutiche, dietetiche e cosmetiche
NO883229D0 (no) Nye benzimidazolderivater, fremgangsmaate for deres fremstilling og farmasoeytisk preparat inneholdende slike derivater.
DE60045508D1 (de) Dalda-analoge und ihre verwendung
EP2144608A4 (en) SUN PROTECTION COMPOSITIONS AND METHODS
TR200000737T2 (tr) İkame edilmiş kroman türevleri.
DK0825197T3 (da) Nye 6-hydroxy- og 6-oxo-androstanderivater, der er aktive i forhold til det cardiovaskulære system, og farmaceutiske præpar
DK0823903T3 (da) Heterocykliske biarylforbindelser, farmaceutiske præparater og kosmetiske sammensætninger, der indeholder dem, og anvendelser
EA200400708A1 (ru) Ингибиторы 11-бета-гидроксистероиддегидрогеназы типа 1
EA200500473A1 (ru) Эритропоэтины длительного действия, которые сохраняют тканезащитную активность эндогенного эритропоэтина
BG106847A (bg) Заместени пиперазинови производни като инхибиторина микрозомалния триглицеридпренасящ протеин (mtp)
DE60310742D1 (de) Extrakt mit antitumoraler und antitoxischer wirkung
ATE344223T1 (de) Vitamin d-analoge
ATE299027T1 (de) Verwendung von übersulfatierten polysacchariden als hiv-hemmer
AU2002214223A1 (en) Long-acting cytokine derivatives and pharmaceutical compositions comprising them

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application